Abstracts

THE COST-EFFECTIVENESS OF AMBISOME FOR ASYMPTOMATIC CRYPTOCOCCAL INFECTION

Screening for cryptococcal antigen (CrAg) among those with advanced HIV disease and treating asymptomatic CrAg+ with fluconazole is lifesaving. However, fluconazole monotherapy still results in 25% mortality.1 Enhanced preemptive treatment options are being evaluated to prevent cryptococcal meningitis. Single dose Ambisome (at 10mg/kg) plus fluconazole is being prospectively evaluated for preemptive treatment in asymptomatic CrAg+.…

CRYPTOCOCCAL ANTIGENEMIA IN HIV PATIENTS WITH VIROLOGIC FAILURE IN UGANDA

Cryptococcal antigen (CrAg) precedes fulminant cryptococcal meningitis, and preemptive treatment of those CrAg positive before development of meningitis is life-saving. The World Health Organization recommends screening and preemptive treatment for those with a CD4<100 cells/µL who are initiating ART. However, the proportion of patients presenting with fulminant cryptococcal meningitis is increasingly ART-experienced. It is not…

CYTOMEGALOVIRUS VIREMIA ASSOCIATED WITH MORTALITY IN CRYPTOCOCCAL MENINGITIS

Cryptococcal meningitis and tuberculosis are both major causes of morbidity and mortality in persons with advanced HIV disease. Cytomegalovirus (CMV) viremia may be associated with increased mortality in HIV-infected persons with tuberculosis. It is not known if CMV viremia is associated with mortality in other AIDS-related opportunistic infections. We prospectively enrolled HIV-infected Ugandans with cryptococcal…

PNEUMOCOCCAL VACCINATION IN HIV+ ADULT PATIENTS ON SUPPRESSIVE ART, 2010-2017

There is little information on the efficacy of the pneumococcal vaccines (PV), especially of the pneumococcal conjugate vaccines (PCV), in successfully treated patients in the modern ART era. Case-control study in a tertiary, University Hospital in Madrid. Cases were HIV-patients admitted to the hospital (2010-2017) with a microbiologically confirmed infection due to S. pneumoniae (from…

QUANTIFICATION OF CD64: A PREDICTIVE BIOMARKER FOR PROGRESSION TO ACTIVE TUBERCULOSIS

To reach the goal of end-Tuberculosis strategy, new biomarkers are needed to identify active tuberculosis (TB). Currently, only QuantiFERON® TB assay (QTF) is used in peripheral blood for screening tuberculosis infection. However, this method cannot distinguish active from latent TB infection (LTBI). Recent studies show a transcriptional increase of several genes, including CD64, which code…